Fundraising Fox
Epilepsy GTx
9 employees on LinkedIn · 6 known investors
Find your way into Epilepsy GTx
Sign up to see every warm intro you have to Epilepsy GTx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Epilepsy GTx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
EpilepsyGTx is a preclinical-stage biotech developing gene therapies for focal refractory epilepsy (FRE), with the aim of making patients seizure free.
Investors · 6
How we know: AlbionVC's portfolio page · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: XGEN Venture's portfolio page · funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Funding
SEC filings, press & company announcements$33M disclosed across 1 of 2 rounds · 2024–2025
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Epilepsy GTx do?
- EpilepsyGTx is a preclinical-stage biotech developing gene therapies for focal refractory epilepsy (FRE), with the aim of making patients seizure free.
- Who are Epilepsy GTx's investors?
- Epilepsy GTx's investors include AlbionVC, Moonstone Venture Capital, UCL Technology Fund, XGEN Venture, British Business Bank, Health Technology Holding (HTH).
- How much funding has Epilepsy GTx raised?
- Epilepsy GTx has disclosed $33M raised across 1 of its 2 known rounds.